Ali Mojaverian, MD
Critical Care Medicine · Riverside, CANPI 1205829843
Payments from drug & device makers
Across 173 payments — averaging $33.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$1K
- Boston Scientific$1K
- Veran Medical Technologies, Inc.$855
- AstraZeneca$505
- Boehringer Ingelheim$426
- Viatris Specialty LLC$280
- plus $1K from 28 others
What the payments were for
- Travel & lodging$1,86232%
- Food & beverage$3,99768%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 64 | $1,237 |
| Boston Scientific | 5 | $1,081 |
| Veran Medical Technologies, Inc. | 2 | $855 |
| AstraZeneca | 23 | $505 |
| Boehringer Ingelheim | 17 | $426 |
| Viatris Specialty LLC | 8 | $280 |
| Inspire Medical Systems, Inc. | 2 | $257 |
| Electromed, Inc. | 6 | $123 |
| Grifols USA, LLC | 4 | $123 |
| Regeneron Healthcare Solutions, Inc. | 5 | $114 |
| Intuitive Surgical | 1 | $104 |
| Philips North America LLC | 5 | $102 |
| Verona Pharma, Inc. | 3 | $96 |
| Jazz Pharmaceuticals Inc. | 4 | $79 |
| United Therapeutics Corporation | 2 | $53 |
| Lilly USA, LLC | 1 | $35 |
| Novartis | 2 | $34 |
| Insmed, Inc. | 2 | $31 |
| 3b Medical, Inc. | 1 | $31 |
| E.r. Squibb & Sons, L.L.C. | 1 | $29 |
| ANI Pharmaceuticals, Inc. | 1 | $28 |
| Melinta Therapeutics, LLC | 2 | $25 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $23 |
| Mallinckrodt Hospital Products Inc. | 1 | $22 |
| Actelion Pharmaceuticals US, Inc. | 1 | $21 |
| Itamar Medical Inc | 1 | $21 |
| Genentech USA, Inc. | 1 | $19 |
| Johnson & Johnson | 1 | $19 |
| Merck | 1 | $18 |
| Sunovion Pharmaceuticals Inc. | 1 | $17 |
| Pulmonx Corporation | 1 | $17 |
| Shire North American Group Inc | 1 | $17 |
| Abiomed | 1 | $16 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GENERAL - THERAPIES$961
- Spin$842
- NUCALA$362
- Inspire Upper Airway Stimulation System$224
- Yupelri$120
- TEZSPIRE$120
- Da Vinci Surgical System$104
How this compares
$5,874 in reported general payments places this provider in the 80th percentile of 715 critical care medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 155 | $116,730 |
| NucalaMepolizumab | 13 | $45,892 |
| Breo ElliptaFluticasone/Vilanterol | 31 | $22,433 |
| Spiriva RespimatTiotropium Bromide | 30 | $20,700 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 25 | $16,199 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 16 | $9,131 |
| Atrovent HfaIpratropium Bromide | 11 | $8,547 |
| Spiriva HandihalerTiotropium Bromide | 11 | $5,474 |
| Wixela InhubFluticasone Propion/Salmeterol | 24 | $4,901 |
| Fluticasone-VilanterolFluticasone/Vilanterol | 12 | $3,909 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 15 | $3,641 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 124 | $3,195 |
| Levalbuterol Tartrate HfaLevalbuterol Tartrate | 11 | $643 |
| Montelukast Sodium | 58 | $485 |
| Fluticasone Propionate | 32 | $274 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Nucala, Breo Ellipta, Anoro Ellipta | $1,237 | $201,254224 claims |
| Boehringer IngelheimSpiriva Respimat, Combivent Respimat | $426 | $29,83046 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 715 critical care medicine providers in California.
Other critical care medicine in Riverside
- Cedric Franklin RutlandRiverside$3.2M
- Errajith de SilvaRiverside$177K
- Rafael LupercioRedding$14.6M
- Timothy AlbertsonSacramento$7.6M
- Carolyn CalfeeSan Francisco$5M
- Bassam YaghmourOrange$4.4M
- Alex HakimLos Angeles$946K
- Praveen AkuthotaSan Diego$841K
- Wael El MaraachliSan Diego$751K
- Stephen RuossStanford$635K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.